A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

NCT07136467 · tracked via the Priya Life Science UK tracker

Sponsor

AbbVie

Phase

Observational

Started

2025-09-02

Last updated

2026-02-13

Condition(s) studied

Non-Segmental Vitiligo (NSV)Alopecia AreataHidradenitis Suppurativa

Study summary

This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.

Eligibility

Sex

ALL

Min age

12 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS) * Participants Ability to understand study questionnaires, with caregiver support as required for adolescents Exclusion Criteria: * Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study) * Unable or unwilling to comply with study requirements and PRO collection

Primary outcome measure(s)

Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only — Up to Day 1
AASIS- is a scale assessing the severity of AA-related symptoms on daily functioning. Each item scored on a 0-10 Likert scale, where 0 = not present and 10 = as bad as you can imagine Higher total score = greater impact
Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only — Up to Day 1
SALT is a Tool developed to quantify AA-related hair loss Total score of 0-100, with 0 = no hair loss, and 100 = complete hair loss
Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only — Up to Day 1
F-VASI is a quantitative scoring tool used to evaluate the extent and severity of facial vitiligo calculated by multiplying the degree of skin depigmentation of the face
Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only — Up to Day 1
VitiQoL is a 16-item instrument assessing impact of vitiligo on QoL. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"
Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only — Up to Day 1
CDLQI is a10-question index measuring health-related quality of life (HRQoL) over the last 7 days for patients suffering from a skin disease. The DLQI is used in participants aged 16 and over and the CDLQI has been validated from the ages of 4 to 16 years. Each item scored on a 4-point Likert scale, where 0 = not at all/not relevant/question unanswered and 3 = very much. Maximum total score = 30 (highest impact on QoL).
Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only — Up to Day 1
The IHS4 score is calculated as follows: number of nodules (multiplied by 1) + number of abscesses (multiplied by 2) + number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.

Trial sites (116)

Facility	City	Region	Status
Hospital Britanico de Buenos Aires /ID# 278940	Ciudad Autonoma de Buenos Aire	Buenos Aires	Recruiting
Buenos Aires Skin /ID# 277637	Buenos Aires	Argentina	Recruiting
Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 277634	Buenos Aires	Argentina	Recruiting
Hospital Italiano de Buenos Aires /ID# 277636	Buenos Aires	Argentina	Recruiting
Instituto de Neumonología y Dermatología /ID# 277635	Buenos Aires	Argentina	Recruiting
Dermatology Research Institute - Blackfoot Trail /ID# 276548	Calgary	Alberta	Recruiting
Rejuvenation Dermatology - Edmonton Downtown /ID# 276593	Edmonton	Alberta	Recruiting
Alberta Dermatology Consultants /ID# 277187	Edmonton	Alberta	Recruiting
Brunswick Dermatology Center /ID# 276546	Fredericton	New Brunswick	Recruiting
Simcoderm Medical And Surgical Dermatology Centre /ID# 276838	Barrie	Ontario	Recruiting
DermEffects /ID# 276594	London	Ontario	Recruiting
Lynderm Research Inc /ID# 276595	Markham	Ontario	Recruiting
York Dermatology Clinic & Research Centre /ID# 276697	Richmond Hill	Ontario	Recruiting
Dermacentre Recherches /Id# 277593	Pointe-Claire	Quebec	Recruiting
Centro de Inmunología y Genética CIGE SAS /ID# 280793	Medellín	Antioquia	Recruiting
Policlinico Social Del Norte /ID# 280935	Bogotá	Bogota D.C.	Recruiting
Nemocnice Na Bulovce /ID# 275542	Prague	Central Bohemia	Recruiting
Dermafit Centrum /ID# 275863	Pilsen	Plzeň Region	Recruiting
Dermamedest /ID# 275861	Prague	Praha 2	Recruiting
North Estonia Medical Centre /ID# 276933	Tallinn	Harju	Recruiting
Tartu University Hospital /ID# 276932	Tartu	Estonia	Recruiting
Chu Dijon /Id# 277493	Dijon	Bourgogne-Franche-Comté	Recruiting
Centre Hospitalier Regional Universitaire de Besancon - Hopital Jean Minjoz /ID# 277459	Besançon	Doubs	Recruiting
Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 277322	Bordeaux	Gironde	Recruiting
CHU Toulouse - Hopital Larrey /ID# 277321	Toulouse	Haute-Garonne	Recruiting
CHU Rennes - Hôpital PONTCHAILLOU /ID# 277527	Rennes	Ille-et-Vilaine	Recruiting
Centre Hospitalier Régional Universitaire De Tours - Hôpital Trousseau /ID# 277545	Chambray-lès-Tours	Indre-et-Loire	Recruiting
CHU Grenoble - Hopital Michallon /ID# 277501	La Tronche	Isere	Recruiting
Centre Hospitalier de Bretagne Sud /ID# 277559	Lorient	Morbihan	Recruiting
Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy /ID# 277792	Metz	Moselle	Recruiting
CHU Limoges - Dupuytren 2 /ID# 277323	Limoges	New Aquitaine	Recruiting
Médipôle Lyon-Villeurbanne /ID# 277526	Villeurbanne	Rhone	Recruiting
Groupe Hospitalier Du Havre - Hôpital Jacques Monod /ID# 277506	Montivilliers	Seine-Maritime	Recruiting
Hopital Nord Franche-Comté /ID# 277560	Trévenans	Territoire De Belfort	Recruiting
Hôpital d'Instruction des Armées Sainte-Anne /ID# 277458	Toulon	Var	Recruiting
Centre Hospitalier Departemental Vendee (Chd Vendee) /ID# 277317	La Roche-sur-Yon	Vendee	Recruiting
Centre Hospitalier de Calais /ID# 277320	Calais	France	Recruiting
Centre Hospitalier Public du Cotentin - Hôpital Pasteur /ID# 279613	Cherbourg	France	Recruiting
Cideazur /ID# 277316	Nice	France	Recruiting
Centre De Santé Sabouraud /ID# 278409	Paris	France	Recruiting

+ 76 more sites — see the full list on the official registry below.

More AbbVie trials in the UK

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) Active, not recruiting

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) Active, not recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma Active, not recruiting

Other trials for the same condition

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Recruiting

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib Active, not recruiting

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07136467 on ClinicalTrials.gov ↗ ← All trials in the UK